Tema Etfs LLC Acquires Shares of 736 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Tema Etfs LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 736 shares of the company's stock, valued at approximately $304,000.

A number of other institutional investors have also recently bought and sold shares of IDXX. Hurley Capital LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $29,000. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories during the fourth quarter worth $30,000. Colonial Trust Co SC increased its holdings in shares of IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after purchasing an additional 39 shares during the last quarter. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at $38,000. Finally, Itau Unibanco Holding S.A. raised its position in shares of IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after purchasing an additional 81 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX traded up $3.96 during trading hours on Thursday, reaching $504.83. 555,044 shares of the company were exchanged, compared to its average volume of 649,538. The business has a 50 day moving average of $437.40 and a 200 day moving average of $433.24. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.60. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The company has a market capitalization of $40.60 billion, a P/E ratio of 47.31, a P/E/G ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. IDEXX Laboratories's revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the business earned $2.71 earnings per share. Research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research analyst reports. Piper Sandler lifted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Barclays boosted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Morgan Stanley increased their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday. Finally, Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average price target of $536.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.